Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein
Abstract In this study, a novel theranostic radiopharmaceutical, [13xLa]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132La (half-life: 4.59 h, 42.1% β⁺) and 135La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural b...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-91716-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850252146563350528 |
|---|---|
| author | Ali Shirpour Asghar Hadadi Samaneh Zolghadri Sara Vosoughi Saeed Rajabifar |
| author_facet | Ali Shirpour Asghar Hadadi Samaneh Zolghadri Sara Vosoughi Saeed Rajabifar |
| author_sort | Ali Shirpour |
| collection | DOAJ |
| description | Abstract In this study, a novel theranostic radiopharmaceutical, [13xLa]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132La (half-life: 4.59 h, 42.1% β⁺) and 135La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural barium in a 30 MeV cyclotron, achieving high radionuclidic purity (99.9%) and radiochemical purity (RCP > 99%). Stability tests revealed the RCP greater than 91% over 24 h in human serum and PBS buffer. Cellular studies confirmed high binding affinity (KD = 0.51 ± 0.12 nM) and effective internalization of [13xLa]La-FAP-2286 in FAP + tumor cells. Distribution coefficient (log D) measurements demonstrated high hydrophilicity of the complex with a value of − 3.21 ± 0.14. Imaging and biodistribution studies in tumor-bearing mice further confirmed tumor targeting, with significant uptake observed up to 48 h post-injection. These results suggest [13xLa]La-FAP-2286 can be considered a candidate for theranostic applications, offering both practical PET imaging and targeted Auger-electron therapy for cancer treatment. |
| format | Article |
| id | doaj-art-6465d3129df6457486d8a87c49bcfecf |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-6465d3129df6457486d8a87c49bcfecf2025-08-20T01:57:44ZengNature PortfolioScientific Reports2045-23222025-03-0115111310.1038/s41598-025-91716-3Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation proteinAli Shirpour0Asghar Hadadi1Samaneh Zolghadri2Sara Vosoughi3Saeed Rajabifar4Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad UniversityDepartment of Medical Radiation Engineering, Science and Research Branch, Islamic Azad UniversityRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI)Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI)Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI)Abstract In this study, a novel theranostic radiopharmaceutical, [13xLa]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132La (half-life: 4.59 h, 42.1% β⁺) and 135La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural barium in a 30 MeV cyclotron, achieving high radionuclidic purity (99.9%) and radiochemical purity (RCP > 99%). Stability tests revealed the RCP greater than 91% over 24 h in human serum and PBS buffer. Cellular studies confirmed high binding affinity (KD = 0.51 ± 0.12 nM) and effective internalization of [13xLa]La-FAP-2286 in FAP + tumor cells. Distribution coefficient (log D) measurements demonstrated high hydrophilicity of the complex with a value of − 3.21 ± 0.14. Imaging and biodistribution studies in tumor-bearing mice further confirmed tumor targeting, with significant uptake observed up to 48 h post-injection. These results suggest [13xLa]La-FAP-2286 can be considered a candidate for theranostic applications, offering both practical PET imaging and targeted Auger-electron therapy for cancer treatment.https://doi.org/10.1038/s41598-025-91716-3 |
| spellingShingle | Ali Shirpour Asghar Hadadi Samaneh Zolghadri Sara Vosoughi Saeed Rajabifar Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein Scientific Reports |
| title | Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| title_full | Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| title_fullStr | Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| title_full_unstemmed | Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| title_short | Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| title_sort | preclinical evaluation of 13xla la fap 2286 as a novel theranostic agent for tumors expressing fibroblast activation protein |
| url | https://doi.org/10.1038/s41598-025-91716-3 |
| work_keys_str_mv | AT alishirpour preclinicalevaluationof13xlalafap2286asanoveltheranosticagentfortumorsexpressingfibroblastactivationprotein AT asgharhadadi preclinicalevaluationof13xlalafap2286asanoveltheranosticagentfortumorsexpressingfibroblastactivationprotein AT samanehzolghadri preclinicalevaluationof13xlalafap2286asanoveltheranosticagentfortumorsexpressingfibroblastactivationprotein AT saravosoughi preclinicalevaluationof13xlalafap2286asanoveltheranosticagentfortumorsexpressingfibroblastactivationprotein AT saeedrajabifar preclinicalevaluationof13xlalafap2286asanoveltheranosticagentfortumorsexpressingfibroblastactivationprotein |